Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL224402 | 0.96 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL226831 | 0.89 | — | — | |
| SCHEMBL7129642 | 0.83 | ALDH1A1 (0.59) | ALDH1A1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL10723835 | 0.83 | ALDH1A1 (0.59) | ALDH1A1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL9368480 | 0.81 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL5143783 | 0.81 | ALDH1A1 (0.58) | ALDH1A1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL5143781 | 0.81 | ALDH1A1 (0.58) | ALDH1A1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL6608940 | 0.81 | ALDH1A1 (0.58) | ALDH1A1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL13673385 | 0.80 | CHRM1 (0.44) | ALDH1A1KMT2AMEN1NPSR1TSHR | |
| SCHEMBL227602 | 0.80 | PIK3CD (0.42) | ALDH1A1KMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481676-B2 | Azepino[4,5-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9409910-B2 | Azepino[4,5-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9119853-B2 | Sanglifehrin based compounds | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-09-01 | — | — | US | disclosed |
| US-9119853-B2 | Sanglifehrin based compounds | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-09-01 | — | — | US | disclosed |
| EP-2533784-B1 | SANGLIFEHRIN BASED COMPOUNDS | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-04-22 | — | — | EP | disclosed |
| CN-102316732-B | Azepino [4, 5-b] indoles and methods of use | MEDIVATION TECHNOLOGIES INC | 2015-04-01 | — | — | CN | disclosed |
| US-20140213577-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-20140088087-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| EP-1432706-A2 | 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2004052887-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2003027085-A2 | 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-0450066-B1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-5401740-A | FOR INHIBITING PLATELET AGGREGATION | OTSUKA PHARMACEUTICAL CO. (JP) | 1995-03-28 | — | — | US | disclosed |
| US-5227381-A | Anticoagulant | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-13 | — | — | US | disclosed |
| US-5220023-A | Intermediates for inotropic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-06-15 | — | — | US | disclosed |
| US-5120845-A | Treating congestive heart failure | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-06-09 | — | — | US | disclosed |
| EP-0450066-A1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-09 | — | — | EP | disclosed |
| US-5043327-A | Treating mammals with congestive heart failure | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213577-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | HTR2C, HTR5A, HTR4 | ALDH1A1 1048/4885KMT2A 1524/4885MEN1 2100/4885 |
| US-20140088087-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | HTR2C, HTR5A, HTR4 | ALDH1A1 1048/4885KMT2A 1524/4885MEN1 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.